1
Total investments
0
Early stage
0
Mid stage
0
Late stage
6y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Jul 2020
The Boston Chapter of the National Investor Relations Institute (NIRI Boston) is dedicated to the professional advancement of its members by supporting the Investor Relations function. NIRI Boston is committed to fostering a greater understanding of effective and ethical investor relations practices.
Experience · 2 entries
All (2)
Investments (1)
Board (1)
2020
Board Member
Jul 2020
The Boston Chapter of the National Investor Relations Institute (NIRI Boston) is dedicated to the professional advancement of its members by supporting the Investor Relations function. NIRI Boston is committed to fostering a greater understanding of effective and ethical investor relations practices.
2019
Associate Director, Investor Relations
Jul 2019
We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases.
GeneRide™ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies
With GeneRide™, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.
LogicBio has been acquired by Alexion, AstraZeneca Rare Disease. For future updates on our genome editing program, follow Alexion Pharmaceuticals.